KIVU-305

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameKIVU-305
Drug Alias NameKIVU-305
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CEACAM5
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKivu Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesKivu Bioscience Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A